NCT04913337 - Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | Biotech Hunter

Enrollment

179

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

July 31, 2025

Conditions

MesotheliomaGlioblastomaRenal Cell CarcinomaNon Small Cell Lung CancerMelanomaPancreatic Ductal AdenocarcinomaGastric CancerSquamous Cell Carcinoma of Head and NeckCholangiocarcinomaBreast CancerOvarian CancerCervical CancerEndocervical CancerColorectal CancerEsophageal Cancer

Interventions

DRUG

NGM707

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."

DRUG

NGM707 plus pembrolizumab (KEYTRUDA®)

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.~Drug: pembrolizumab (KEYTRUDA®)~Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle."

DRUG

NGM707

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."

DRUG

NGM707

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."

DRUG

NGM707

"Drug: NGM707~NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated."

Trial Locations (27)

235

NGM Clinical Study Site, New Taipei City

704

NGM Clinical Study Site, Tainan City

12206

NGM Clinical Study Site, Albany

20007

NGM Clinical Study Site, Washington D.C.

21201

NGM Clinical Study Site, Baltimore

24060

NGM Clinical Study Site, Blacksburg

29605

NGM Clinical Study Site, Greenville

34232

NGM Clinical Study Site, Sarasota

49546

NGM Clinical Study Site, Grand Rapids

68130

NGM Clinical Study Site, Omaha

75246

NGM Clinical Study Site, Dallas

77030

NGM Clinical Study Site, Houston

78229

NGM Clinical Study Site, San Antonio

78240

NGM Clinical Study Site, San Antonio

78701

NGM Clinical Study Site, Dallas

80124

NGM Clinical Study Site, Lone Tree

90033

NGM Clinical Study Site, Los Angeles

90404

NGM Clinical Study Site, Santa Monica

92663

NGM Clinical Study Site, Newport Beach

94505

NGM Clinical Study Site, Santa Rosa

98684

NGM Clinical Study Site, Vancouver

100225

NGM Clinical Study Site, Taipei

404327

NGM Clinical Study Site, Taichung

02215

NGM Clinical Study Site, Boston

03080

NGM Clinical Study Site, Seoul

05505

NGM Clinical Study Site, Seoul

06351

NGM Clinical Study Site, Seoul